Methocarbamol and Aptiom drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Methocarbamol and Aptiom. Common interactions include seizure among females and agitation among males.

The phase IV clinical study analyzes what interactions people who take Methocarbamol and Aptiom have. It is created by eHealthMe based on reports of 6 people who take Methocarbamol and Aptiom from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 01, 2022

6 people who take Methocarbamol and Aptiom together, and have interactions are studied.


What is Methocarbamol?

Methocarbamol has active ingredients of methocarbamol. It is often used in muscle spasms. eHealthMe is studying from 14,406 Methocarbamol users for its effectiveness, alternative drugs and more.

What is Aptiom?

Aptiom has active ingredients of eslicarbazepine acetate. eHealthMe is studying from 2,019 Aptiom users for its effectiveness, alternative drugs and more.

Number of Methocarbamol and Aptiom reports submitted per year:

Methocarbamol and Aptiom drug interactions.

Common Methocarbamol and Aptiom drug interactions by gender *:

female:

  1. Seizure
  2. Ammonia increased
  3. Fall
  4. Haematoma
  5. Infection
  6. Lower respiratory tract infection
  7. Pneumonia
  8. Snoring
  9. Tinnitus
  10. Tooth disorder

male:

  1. Agitation
  2. Arthritis
  3. Fall
  4. Fatigue
  5. Haematoma
  6. Intervertebral disc degeneration
  7. Joint injury
  8. Palpitations
  9. Road traffic accident
  10. Seizure

Common Methocarbamol and Aptiom drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Seizure
  2. Agitation
  3. Drug ineffective
  4. Fall
  5. Fatigue
  6. Haematoma
  7. Intervertebral disc degeneration
  8. Joint injury
  9. Palpitations
  10. Road traffic accident

60+:

n/a

* Approximation only. Some reports may have incomplete information.

Do you take Methocarbamol and Aptiom?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Methocarbamol and Aptiom:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Methocarbamol interactions:

Browse all interactions between Methocarbamol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Aptiom interactions:

Browse all interactions between Aptiom and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on methocarbamol and eslicarbazepine acetate (the active ingredients of Methocarbamol and Aptiom, respectively), and Methocarbamol and Aptiom (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Methocarbamol and Aptiom.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: